Exelixis Appoints Executive Vice President and General Counsel

13-02-2014 Business Wire HealthComments (0)

BiotechnologyExelixisPharmaceutical

Exelixis (NASDAQ: EXEL) today announced the appointment of Jeffrey J. Hessekiel, J.D., as executive vice president and general counsel. Mr. Hessekiel is a veteran legal professional with more than a decade of experience in the biopharmaceutical industry, as well as six years spent in general corporate and litigation practice in Silicon Valley. His legal expertise in pharmaceutical commercialization, compliance, and risk management will benefit

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top